Should adjuvant weekly paclitaxel be considered less efficacious than anthracyclines plus cyclophosphamide for lower-risk patients with early-stage breast cancer?

Authors	Vito Amoroso, Rebecca Pedersini, Phoebe Sharratt, Lucia Vassalli, Laura Ferrari, Sandra Sigala, Edda Simoncini, Alfredo Berruti
Journal	Journal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 33 Issue 3 Pg. 290 (Jan 20 2015) ISSN: 1527-7755 [Electronic] United States
PMID	25512451 (Publication Type: Letter, Comment)
Chemical References	Paclitaxel
Topics	Antineoplastic Combined Chemotherapy Protocols (therapeutic use) Breast Neoplasms (drug therapy) Female Humans Paclitaxel (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!